Yatharth Hospital & Trauma Care Services Ltd
YATHARTHYatharth Hospital & Trauma Care Services Ltd's earnings have outrun its stock. EPS grew +34.3% in a year against a +28.6% price move.
The sharpest disagreement: Promoters moved −10.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (17 weeks in) while the P/E sits at the 79th percentile of its own 3-year range. Underneath, the last four quarters read improving — profit +15.4% year on year, and 85% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Yatharth Hospital & Trauma Care Services Ltd trades at ₹818, in a confirmed uptrend and 17 weeks into that stage. That is +9.3% against its own 200-day average. It sits at 85% of a 52-week range of ₹551 to ₹866. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (1 week and counting).
Today the stock is in a confirmed uptrend — week 17 of stage 2, confirmed. At ₹818 it trades +9.3% versus its 200-day average and sits at 85% of its 52-week range (₹551–₹866).
Against the market, two honest reads. Cumulative: over the last 3.0 years the stock moved +148% while the NIFTY 500 moved +39% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (1 week and counting; last ahead the week of 2026-07-24) — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Yatharth Hospital & Trauma Care Services Ltd trades at 45.0× P/E, at the pricey end of its own range (79th percentile). Its long-run median P/E is 38.7×, measured across 3.0 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 45.0× is at the pricey end of its own range (79th percentile), against a long-run median of 38.7× measured over 3.0 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
Why the multiple sits where it does: over the past year annual EPS moved +34.3% against a +28.6% price move — earnings outran the price, pushing the multiple DOWN its own range.
The price move, decomposed: over 3y, of the +35.3%/yr price move, ~+21.9%/yr came from earnings growth and ~+13.4 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
The PEG ratio and its quarterly curve, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.5% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Yatharth Hospital & Trauma Care Services Ltd reads as mixed on its fundamental arc. Mixed — revenue growth is rising at +47.4% (single-quarter readings) while profit growth is decelerating from its peak at +15.4% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read is built from 10 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +40.3% | +36.2% | +41.2% | — |
| Profit | +29.8% | +37.1% | +53.4% | — |
| EPS | +34.3% | +21.9% | +10.4% | — |
| Share price | +28.6% | +35.3% | — | — |
4-Factor Sector Score
48.2/100 — rank 12 of 19 in Hospitals · 78% evidence confidence
Yatharth Hospital & Trauma Care Services Ltd scores 48.2 out of 100 against the 19 companies it is compared with in Hospitals, ranking 12. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 19.5 + 11.7 + 8.8 + 8.2 = 48.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Yatharth Hospital & Trauma Care Services Ltd reported ₹342 Cr of revenue in the Mar 26 quarter, +47.4% year on year. That is the 10th straight quarter of year-on-year growth. Over 9 years it has compounded at 37.0% a year. The last full year, FY26, came in at ₹1,207 Cr. The last four reported quarters add to ₹1,199 Cr.
FY26 revenue came in at ₹1,207 Cr (+40.3% on the year), capping 9 years at 37.0% compound. The latest quarter (Mar 26) printed ₹342 Cr, +47.4% year on year — the 10th consecutive quarter of year-over-year growth.
Pace check: the last four quarters averaged +35.8% growth against the decade's 37.0% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +36.1% over the last 4 quarters against +33.7%/yr over the last 8 — stabilising; TTM profit +31.5% vs +22.5%/yr — accelerating.
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Yatharth Hospital & Trauma Care Services Ltd's operating margin is 23.0% in the Mar 26 quarter, −2.0 percentage points against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 22.0% to 32.0%. The current quarter sits inside that band.
The latest quarter's operating margin is 23.0%, −2.0 pp against the same quarter a year ago. Across 10 fiscal years the operating margin has ranged 22.0%–32.0%.
🚨 Why the margin moved: operating margin went −1.2 pp year on year while gross margin went +1.9 pp — the loss came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Yatharth Hospital & Trauma Care Services Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, +15.4% year on year. It is the 10th consecutive quarter of growth. Full-year FY26 profit was ₹170 Cr. The 9-year compound rate is 56.6%. That is 13.2% of the quarter's revenue. The same quarter a year earlier earned ₹39.0 Cr.
Mar 26 profit was ₹45.0 Cr, +15.4% year on year — the 10th consecutive quarter of growth. On the full year, FY26 printed ₹170 Cr (+29.8%), and the 9-year compound rate is 56.6%.
Why profit moved: revenue contributed +47.4% and the margin −2.0 pp — the quarter was revenue-led despite a thinner margin.
Pace comparison, last four quarters: profit +32.8% vs revenue +35.8%. Profit is growing slower than sales — costs are eating the growth before it reaches the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 85% of Yatharth Hospital & Trauma Care Services Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹205 Cr of operating cash against ₹170 Cr of profit. After ₹613 Cr of capital spending, ₹−408 Cr was left as free cash.
FY26: operating cash of ₹205 Cr against reported profit of ₹170 Cr, leaving free cash of ₹−408 Cr after ₹613 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 85% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 85%: the cash cycle tightened 88 days between FY21 and FY26 — cash that used to wait in the cycle now reaches the bank sooner.
Router verdict: the bigger cash user is investment — capital spending ran 7.1× depreciation over three years, so the next section's job is to check what that build-out is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Yatharth Hospital & Trauma Care Services Ltd's cash conversion cycle runs −26 days in FY26, down from 62 days in FY21. Capital spending ran ₹1,227 Cr over the last 3 years. At FY26 sales of ₹1,207 Cr each day of that cycle holds about ₹3.3 Cr, so roughly ₹−86.0 Cr sits inside the business at any moment.
FY26: debtors at 113 days, inventory at 32 days — roughly 1.1 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −26 days, tighter than FY21's 62.
The full loop: cash goes out to suppliers and production on day 0; stock waits 32 days to sell; customers pay about 113 days after that; and suppliers themselves are paid at 171 days — netting out to the −26-day cycle.
In money terms: at FY26 sales of ₹1,207 Cr, each day of the cycle holds about ₹3.3 Cr — so the −26-day loop keeps roughly ₹−86.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹1,227 Cr over the last 3 fiscal years against ₹174 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹102 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Yatharth Hospital & Trauma Care Services Ltd earns a ROCE of 12% in FY26. That is up from a trough of 6% in FY19. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 14.1% net margin on 0.53× asset turns.
FY26 ROCE is 12%, recovered from a FY19 trough of 6% — the full ladder below shows the fall and the climb, undoctored.
Why the return is what it is — the wiring (FY26): 14.1% net margin × 0.53× asset turns × 1.28× balance-sheet leverage ≈ 9.6% on equity. Margin does its share; leverage is modest — this is an earned return, not a borrowed one.
The quarterly return curves and the return-on-invested-capital overlay, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.5% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Yatharth Hospital & Trauma Care Services Ltd carries ₹264 Cr of borrowings against ₹1,780 Cr of equity in FY26, a debt-to-equity of 0.15. Operating profit covers the interest bill 42×. Over 5 years borrowings went from ₹193 Cr to ₹264 Cr. Capital spending ran ₹1,227 Cr across the last 3 of those years.
FY26: borrowings of ₹264 Cr against equity of ₹1,780 Cr — a debt-to-equity of 0.15. Operating profit covers the interest bill 42×. Over 5 years borrowings went from ₹193 Cr to ₹264 Cr while capital spending ran ₹1,227 Cr in just the last 3 — part of the build-out is riding on borrowed money.
The total-debt and debt-to-equity series, which only the second data source carries, are not drawn on this page: its two data sources disagree by up to 4.5% on reported income across 14 comparable periods. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Promoters cut 10.7 points of Yatharth Hospital & Trauma Care Services Ltd over 8 quarters, the biggest move on the register. That takes promoters to 55.8% of the company. Domestic institutions moved +1.4 points over the same window, to 10.8%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Promoters: −10.7 points over 8 quarters to 55.8%; Domestic institutions: +1.4 points over 8 quarters to 10.8%; Foreign institutions: +0.7 points over 8 quarters to 5.6%.
🚨 Why the register moved: promoters drove it (−10.7 points), absorbed on the other side by domestic institutions (+1.4 points) — distribution into the market’s bid.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Yatharth Hospital & Trauma Care Services Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1KMC Speciality Hospitals (India) Ltd524520 | 82.1/100Sector-leading setup78% evidence | LEADER | 30.8/35 Revenue 32.5% · PAT 100% · OPM change 6 pp 83% evidence | 20.6/25 ROCE 26% · OPM 31% 76% evidence | 11.2/20 P/E 44.5× · PEG — 50% evidence | 19.5/20 RS sector 34% · RS bench 44.3% · 1Y 97.6%12 of 12 weeks ahead 100% evidence |
| Exact sum: 30.8 + 20.6 + 11.2 + 19.5 = 82.1 · Decision use: Confirmed research leader: earnings, capital efficiency and relative strength agree. Move to management, catalyst and risk diligence. | ||||||
| 2Artemis Medicare Services LtdARTEMISMED | 67.9/100Favorable setup96% evidence | LEADER | 24.4/35 Revenue 15.5% · PAT 24.1% · OPM change 3 pp 88% evidence | 12.0/25 ROCE 14.6% · OPM 18% 100% evidence | 14.4/20 P/E 44.6× · PEG 1.09 100% evidence | 17.1/20 RS sector 8.2% · RS bench 17.1% · 1Y 24.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 24.4 + 12 + 14.4 + 17.1 = 67.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 3Sakar Healthcare LtdSAKAR | 67.6/100Favorable setup87% evidence | LEADER | 32.2/35 Revenue 43.9% · PAT 71.4% · OPM change 5 pp 95% evidence | 11.0/25 ROCE 12.7% · OPM 29% 95% evidence | 6.9/20 P/E 54.6× · PEG — 50% evidence | 17.5/20 RS sector 57% · RS bench 68.5% · 1Y 144.1%12 of 12 weeks ahead 100% evidence |
| Exact sum: 32.2 + 11 + 6.9 + 17.5 = 67.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 4Apollo Hospitals Enterprise LtdAPOLLOHOSP | 67.1/100Favorable setup78% evidence | LEADER | 23.6/35 Revenue 15.8% · PAT 33% · OPM change 1 pp 83% evidence | 15.4/25 ROCE 17.9% · OPM 15% 76% evidence | 12.6/20 P/E 65.8× · PEG — 50% evidence | 15.5/20 RS sector 5.2% · RS bench 13.7% · 1Y 19.9%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 15.4 + 12.6 + 15.5 = 67.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5Rainbow Childrens Medicare LtdRAINBOW | 58.0/100Mixed-positive evidence100% evidence | BREAKING OUT | 18.0/35 Revenue 18.3% · PAT 12.4% · OPM change 0 pp 100% evidence | 17.1/25 ROCE 17.4% · OPM 29% 100% evidence | 7.3/20 P/E 54.1× · PEG 2.97 100% evidence | 15.6/20 RS sector 4% · RS bench 12.4% · 1Y -2%12 of 12 weeks ahead 100% evidence |
| Exact sum: 18 + 17.1 + 7.3 + 15.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6Max Healthcare Institute LtdMAXHEALTH | 57.8/100Mixed-positive evidence90% evidence | TURNING | 25.1/35 Revenue 19.1% · PAT 34% · OPM change 1 pp 88% evidence | 15.8/25 ROCE 14.7% · OPM 28% 100% evidence | 10.8/20 P/E 72.1× · PEG 1.73 100% evidence | 6.1/20 RS sector -7.9% · RS bench 0.1% · 1Y -14.2%2 of 10 weeks ahead 70% evidence |
| Exact sum: 25.1 + 15.8 + 10.8 + 6.1 = 57.8 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.9% and the one-year return is -14.2%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 7Kovai Medical Center & Hospital LtdKOVAI | 54.6/100Mixed-positive evidence96% evidence | FADING | 17.8/35 Revenue 15.8% · PAT 16.2% · OPM change -1 pp 88% evidence | 21.3/25 ROCE 22.6% · OPM 27% 100% evidence | 10.4/20 P/E 26.3× · PEG 1.51 100% evidence | 5.1/20 RS sector -7.4% · RS bench 0.2% · 1Y -3.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 17.8 + 21.3 + 10.4 + 5.1 = 54.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 8Dr Agarwals Eye Hospital LtdDRAGARWQ | 54.3/100Mixed-positive evidence90% evidence | ASLEEP | 19.6/35 Revenue 18.6% · PAT 27.8% · OPM change -4 pp 88% evidence | 16.8/25 ROCE 17.4% · OPM 28% 100% evidence | 10.6/20 P/E 34.6× · PEG 1.72 100% evidence | 7.3/20 RS sector -4% · RS bench -1% · 1Y 13.4%4 of 7 weeks ahead 70% evidence |
| Exact sum: 19.6 + 16.8 + 10.6 + 7.3 = 54.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 9Global Health LtdMEDANTA | 54.1/100Mixed-positive evidence100% evidence | LEADER | 12.3/35 Revenue 21.3% · PAT 3.4% · OPM change -2 pp 100% evidence | 13.9/25 ROCE 17.1% · OPM 22% 100% evidence | 11.3/20 P/E 66× · PEG 1.11 100% evidence | 16.6/20 RS sector 4.5% · RS bench 13% · 1Y 6.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.3 + 13.9 + 11.3 + 16.6 = 54.1 · Decision use: Price leads the evidence: RS versus the benchmark is 13%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 10Indraprastha Medical Corporation LtdINDRAMEDCO | 52.2/100Mixed-positive evidence90% evidence | ASLEEP | 12.4/35 Revenue 9.3% · PAT 13.7% · OPM change -1 pp 88% evidence | 18.6/25 ROCE 35.8% · OPM 17% 100% evidence | 17.2/20 P/E 18.3× · PEG 0.92 100% evidence | 4.0/20 RS sector -8.4% · RS bench -17.3% · 1Y -20.2%0 of 10 weeks ahead 70% evidence |
| Exact sum: 12.4 + 18.6 + 17.2 + 4 = 52.2 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 11Fortis Healthcare LtdFORTIS | 50.2/100Mixed-positive evidence78% evidence | FADING | 23.6/35 Revenue 17.3% · PAT 31.5% · OPM change 1 pp 83% evidence | 12.8/25 ROCE 13.4% · OPM 23% 76% evidence | 9.0/20 P/E 67.5× · PEG — 50% evidence | 4.8/20 RS sector -7.3% · RS bench 0.2% · 1Y 11.8%8 of 12 weeks ahead 100% evidence |
| Exact sum: 23.6 + 12.8 + 9 + 4.8 = 50.2 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -7.3% and the one-year return is 11.8%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 12Yatharth Hospital & Trauma Care Services Ltdthis pageYATHARTH | 48.2/100Mixed-negative evidence78% evidence | FADING | 19.5/35 Revenue 36.1% · PAT 31.5% · OPM change -2 pp 83% evidence | 11.7/25 ROCE 12.4% · OPM 23% 76% evidence | 8.8/20 P/E 45× · PEG — 50% evidence | 8.2/20 RS sector 0.2% · RS bench 8.1% · 1Y 30.6%11 of 12 weeks ahead 100% evidence |
| Exact sum: 19.5 + 11.7 + 8.8 + 8.2 = 48.2 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 13GPT Healthcare LtdGPTHEALTH | 47.9/100Mixed-negative evidence70% evidence | TURNING | 10.3/35 Revenue 16% · PAT -14% · OPM change -2 pp 83% evidence | 18.5/25 ROCE 19.9% · OPM 18% 95% evidence | 11.2/20 P/E 32.5× · PEG — 15% evidence | 7.9/20 RS sector -15.8% · RS bench 17.9% · 1Y 5.9%10 of 10 weeks ahead 70% evidence |
| Exact sum: 10.3 + 18.5 + 11.2 + 7.9 = 47.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Aster DM Quality Care LtdASTERDM | 39.4/100Mixed-negative evidence96% evidence | LEADER | 12.6/35 Revenue 12.2% · PAT -80% · OPM change 1 pp 88% evidence | 9.8/25 ROCE 11.4% · OPM 19% 100% evidence | 1.5/20 P/E 176× · PEG 3.07 100% evidence | 15.5/20 RS sector 10.8% · RS bench 19.6% · 1Y 41.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 12.6 + 9.8 + 1.5 + 15.5 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 19.6%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 15Krishna Institute of Medical Sciences LtdKIMS | 39.4/100Mixed-negative evidence78% evidence | LEADER | 10.4/35 Revenue 28.7% · PAT -41.5% · OPM change -6 pp 83% evidence | 9.2/25 ROCE 9.3% · OPM 19% 76% evidence | 5.5/20 P/E 136× · PEG — 50% evidence | 14.3/20 RS sector 3.7% · RS bench 12% · 1Y 5.6%10 of 12 weeks ahead 100% evidence |
| Exact sum: 10.4 + 9.2 + 5.5 + 14.3 = 39.4 · Decision use: Price leads the evidence: RS versus the benchmark is 12%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 16Narayana Hrudayalaya LtdNH | 39.3/100Mixed-negative evidence87% evidence | TURNING | 12.6/35 Revenue 59.6% · PAT 3.8% · OPM change -5 pp 100% evidence | 11.6/25 ROCE 15.5% · OPM 17% 100% evidence | 6.1/20 P/E 48.1× · PEG 3 65% evidence | 9.0/20 RS sector -4.3% · RS bench 9.2% · 1Y 1.9%5 of 10 weeks ahead 70% evidence |
| Exact sum: 12.6 + 11.6 + 6.1 + 9 = 39.3 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Healthcare Global Enterprises LtdHCG | 35.9/100Mixed-negative evidence65% evidence | TURNING | 13.1/35 Revenue 14.5% · PAT -53.4% · OPM change 1.1 pp 83% evidence | 7.4/25 ROCE 8.3% · OPM 19.2% 76% evidence | 8.5/20 P/E 349× · PEG — 15% evidence | 6.9/20 RS sector -8.1% · RS bench 3.4% · 1Y 18.5%8 of 10 weeks ahead 70% evidence |
| Exact sum: 13.1 + 7.4 + 8.5 + 6.9 = 35.9 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 18Shalby LtdSHALBY | 30.7/100Adverse evidence69% evidence | ASLEEP | 15.6/35 Revenue 4.8% · PAT 100% · OPM change 2 pp 62% evidence | 2.5/25 ROCE 6.5% · OPM 10% 95% evidence | 9.1/20 P/E 46.6× · PEG — 50% evidence | 3.5/20 RS sector -28.4% · RS bench -14.9% · 1Y -22.3%6 of 10 weeks ahead 70% evidence |
| Exact sum: 15.6 + 2.5 + 9.1 + 3.5 = 30.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 19Jupiter Life Line Hospitals LtdJLHL | 29.8/100Adverse evidence100% evidence | BASING | 8.4/35 Revenue 14.7% · PAT -3.1% · OPM change -3 pp 100% evidence | 10.5/25 ROCE 14.8% · OPM 19% 100% evidence | 6.4/20 P/E 56.9× · PEG 3.44 100% evidence | 4.5/20 RS sector -74.8% · RS bench 17.9% · 1Y -77.2%3 of 12 weeks ahead 100% evidence |
| Exact sum: 8.4 + 10.5 + 6.4 + 4.5 = 29.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led NIFTY 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is Yatharth Hospital & Trauma Care Services Ltd's share price today?
Yatharth Hospital & Trauma Care Services Ltd trades at ₹818, +28.6% over the past year. The company is valued at ₹7,886 Cr. The stock sits at 85% of its 52-week range of ₹551–₹866, +9.3% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 17 weeks in. — as of 31 July 2026.
What were Yatharth Hospital & Trauma Care Services Ltd's latest quarterly results?
Yatharth Hospital & Trauma Care Services Ltd reported revenue of ₹342 Cr and net profit of ₹45.0 Cr for the Mar 26 quarter. Revenue rose 47.4% and profit rose 15.4% year on year. Earnings per share were ₹4.93. The operating margin was 23.0%, 2.0 pp lower than a year earlier. — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's revenue?
Yatharth Hospital & Trauma Care Services Ltd reported revenue of ₹342 Cr in the Mar 26 quarter, +47.4% year on year. For the full FY26 fiscal year, revenue was ₹1,207 Cr (+40.3%). Over the last 9 years revenue compounded at 37.0% a year. — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's profit?
Yatharth Hospital & Trauma Care Services Ltd earned ₹45.0 Cr of net profit in the Mar 26 quarter, +15.4% year on year — the 10th straight quarter of growth. Full-year FY26 profit was ₹170 Cr. The operating margin ran 23.0% in the latest quarter. — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's market cap?
Yatharth Hospital & Trauma Care Services Ltd's market capitalisation is ₹7,886 Cr at a share price of ₹818. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's P/E ratio?
Yatharth Hospital & Trauma Care Services Ltd trades at a P/E of 45.0×, at the 79th percentile of its own 3-year range, against a long-run median of 38.7×. This is a comparison with the stock's own history, not a value call — as of 31 July 2026.
Does Yatharth Hospital & Trauma Care Services Ltd pay a dividend?
No — Yatharth Hospital & Trauma Care Services Ltd has recorded a dividend payout of 0% of profit in each of its last 10 reported fiscal years, so there is no payout history to quote. That is a reading of the filed annual statements, not an estimate. — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd overvalued?
On its own history, Yatharth Hospital & Trauma Care Services Ltd looks expensive against its own history: its P/E of 45.0× sits at the 79th percentile of its 3-year range (long-run median 38.7×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd growing?
Yes — Yatharth Hospital & Trauma Care Services Ltd is growing: latest-quarter revenue +47.4% year on year, profit +15.4%, and the margin −2.0 pp at 23.0%. The 9-year compound rates are 37.0% (revenue) and 56.6% (profit). The earnings engine currently reads: improving — as of 31 July 2026.
How is Yatharth Hospital & Trauma Care Services Ltd performing?
Yatharth Hospital & Trauma Care Services Ltd is in a confirmed uptrend, 17 weeks in. Its latest quarter's revenue rose 47.4% and profit rose 15.4% year on year. Against the NIFTY 500 it has been behind on a trailing-13-week view for 1 week. — as of 31 July 2026.
What stage is Yatharth Hospital & Trauma Care Services Ltd in?
Mixed — revenue growth is rising at +47.4% (single-quarter readings) while profit growth is decelerating from its peak at +15.4% (single-quarter readings) — the curves disagree, so the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +47.4% latest, profit growth +15.4% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 17 of stage 2), trading +9.3% versus its 200-day average and at 85% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd beating the market?
Not lately — on a trailing-13-week view Yatharth Hospital & Trauma Care Services Ltd is currently behind the NIFTY 500 (1 week and counting; last ahead the week of 2026-07-24), the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 3.0 years the stock moved +148% against the NIFTY 500's +39% — ahead of the index over the full window. — as of 31 July 2026.
Will Yatharth Hospital & Trauma Care Services Ltd's share price go up?
This page publishes no price forecast for Yatharth Hospital & Trauma Care Services Ltd. What it measures instead: the share price is ₹818, the price is in a confirmed uptrend 17 weeks in. Its P/E of 45.0× sits at the 79th percentile of its own 3-year range. — as of 31 July 2026.
Who owns Yatharth Hospital & Trauma Care Services Ltd?
Promoters hold 55.8% of Yatharth Hospital & Trauma Care Services Ltd, foreign institutions 5.6%, domestic institutions 10.8% and the public 27.7% (latest quarter). The biggest move on the register over the last two years: Promoters cut 10.7 points over 8 quarters. — as of 31 July 2026.
Does Yatharth Hospital & Trauma Care Services Ltd have too much debt?
No — Yatharth Hospital & Trauma Care Services Ltd's debt-to-equity is 0.15, and operating profit covers the interest bill 42×. FY26 borrowings were ₹264 Cr against equity of ₹1,780 Cr. The returns on this page are earned, not borrowed — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's capex?
Yatharth Hospital & Trauma Care Services Ltd spent ₹1,227 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. Depreciation over the same years was ₹174 Cr. — as of 31 July 2026.
What is Yatharth Hospital & Trauma Care Services Ltd's cash flow?
Yatharth Hospital & Trauma Care Services Ltd generated ₹205 Cr of operating cash flow in FY26 and ₹−408 Cr of free cash flow after ₹613 Cr of capital spending. Reported profit that year was ₹170 Cr, so operating cash ran ahead of profit. Cash-flow resolution for India is annual. — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd's profit real cash?
Yes — over the last 3 fiscal years, 85% of Yatharth Hospital & Trauma Care Services Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹205 Cr against reported profit of ₹170 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 31 July 2026.
Where is Yatharth Hospital & Trauma Care Services Ltd in its business cycle?
Yatharth Hospital & Trauma Care Services Ltd's FY26 operating margin was 24.0%, against a 10-year band of 22.0%–32.0%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 23.0%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 31 July 2026.
What could break the Yatharth Hospital & Trauma Care Services Ltd story?
The sharpest disagreement: Promoters moved −10.7 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 31 July 2026.
Is Yatharth Hospital & Trauma Care Services Ltd a stock worth studying right now?
This is not investment advice. The machine read: Yatharth Hospital & Trauma Care Services Ltd's earnings have outrun its stock. EPS grew +34.3% in a year against a +28.6% price move. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 31 July 2026.